Literature DB >> 16518375

Targeting multidrug resistance in cancer.

Gergely Szakács1, Jill K Paterson, Joseph A Ludwig, Catherine Booth-Genthe, Michael M Gottesman.   

Abstract

Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518375     DOI: 10.1038/nrd1984

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  1042 in total

1.  Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8.

Authors:  Catherine L Watkins; Edward J Sayers; Chris Allender; David Barrow; Christopher Fegan; Paul Brennan; Arwyn T Jones
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

2.  Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro.

Authors:  Forrest M Kievit; Freddy Y Wang; Chen Fang; Hyejung Mok; Kui Wang; John R Silber; Richard G Ellenbogen; Miqin Zhang
Journal:  J Control Release       Date:  2011-01-26       Impact factor: 9.776

Review 3.  Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes.

Authors:  Marina Pajic; Christopher J Scarlett; David K Chang; Robert L Sutherland; Andrew V Biankin
Journal:  Hum Genet       Date:  2011-04-23       Impact factor: 4.132

4.  Antibiotic That Inhibits the ATPase Activity of an ATP-Binding Cassette Transporter by Binding to a Remote Extracellular Site.

Authors:  Leigh M Matano; Heidi G Morris; Anthony R Hesser; Sara E S Martin; Wonsik Lee; Tristan W Owens; Emaline Laney; Hidemasa Nakaminami; David Hooper; Timothy C Meredith; Suzanne Walker
Journal:  J Am Chem Soc       Date:  2017-07-28       Impact factor: 15.419

5.  The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines.

Authors:  Sung-Han Hsiao; Megumi Murakami; Ni Yeh; Yan-Qing Li; Tai-Ho Hung; Yu-Shan Wu; Suresh V Ambudkar; Chung-Pu Wu
Journal:  Cancer Lett       Date:  2018-07-18       Impact factor: 8.679

6.  The inhibitory effects of mitragynine on P-glycoprotein in vitro.

Authors:  Noradliyanti Rusli; Azimah Amanah; Gurjeet Kaur; Mohd Ilham Adenan; Shaida Fariza Sulaiman; Habibah Abdul Wahab; Mei Lan Tan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-02       Impact factor: 3.000

7.  Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug-gene co-delivery to cancer cells.

Authors:  Chih-Kuang Chen; Wing-Cheung Law; Ravikumar Aalinkeel; Yun Yu; Bindukumar Nair; Jincheng Wu; Supriya Mahajan; Jessica L Reynolds; Yukun Li; Cheng Kee Lai; Emmanuel S Tzanakakis; Stanley A Schwartz; Paras N Prasad; Chong Cheng
Journal:  Nanoscale       Date:  2014       Impact factor: 7.790

8.  Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells.

Authors:  Abraham H Abouzeid; Niravkumar R Patel; Can Sarisozen; Vladimir P Torchilin
Journal:  Pharm Res       Date:  2014-02-13       Impact factor: 4.200

9.  Identification of the distance between the homologous halves of P-glycoprotein that triggers the high/low ATPase activity switch.

Authors:  Tip W Loo; David M Clarke
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

10.  Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study.

Authors:  Rishil J Kathawala; Kamlesh Sodani; Kang Chen; Atish Patel; Alaa H Abuznait; Nagaraju Anreddy; Yue-Li Sun; Amal Kaddoumi; Charles R Ashby; Zhe-Sheng Chen
Journal:  Mol Cancer Ther       Date:  2014-01-15       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.